JP2023529025A - 抗ウイルス処置としてのアゼラスチン - Google Patents

抗ウイルス処置としてのアゼラスチン Download PDF

Info

Publication number
JP2023529025A
JP2023529025A JP2023516644A JP2023516644A JP2023529025A JP 2023529025 A JP2023529025 A JP 2023529025A JP 2023516644 A JP2023516644 A JP 2023516644A JP 2023516644 A JP2023516644 A JP 2023516644A JP 2023529025 A JP2023529025 A JP 2023529025A
Authority
JP
Japan
Prior art keywords
azelastine
virus
cov
sars
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529025A5 (enExample
Inventor
ナギ，エスター
ナギ，ガボール
シヤルト，バレリア
コンラット，ロベルト
Original Assignee
ツェビナ・ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20184767.0A external-priority patent/EP3936132A1/en
Application filed by ツェビナ・ゲーエムベーハー filed Critical ツェビナ・ゲーエムベーハー
Publication of JP2023529025A publication Critical patent/JP2023529025A/ja
Publication of JP2023529025A5 publication Critical patent/JP2023529025A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023516644A 2020-05-29 2021-05-28 抗ウイルス処置としてのアゼラスチン Pending JP2023529025A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20177451 2020-05-29
EP20177451.0 2020-05-29
EP20184767.0 2020-07-08
EP20184767.0A EP3936132A1 (en) 2020-07-08 2020-07-08 Azelastine as antiviral treatment
EP20195740 2020-09-11
EP20195740.4 2020-09-11
EP21171333 2021-04-29
EP21171333.4 2021-04-29
PCT/EP2021/064338 WO2021239943A1 (en) 2020-05-29 2021-05-28 Azelastine as antiviral treatment

Publications (2)

Publication Number Publication Date
JP2023529025A true JP2023529025A (ja) 2023-07-06
JP2023529025A5 JP2023529025A5 (enExample) 2024-06-04

Family

ID=76059910

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516644A Pending JP2023529025A (ja) 2020-05-29 2021-05-28 抗ウイルス処置としてのアゼラスチン

Country Status (21)

Country Link
US (3) US20230201216A1 (enExample)
EP (2) EP3934653B1 (enExample)
JP (1) JP2023529025A (enExample)
KR (1) KR20230021009A (enExample)
CN (1) CN116406273A (enExample)
AU (1) AU2021279280A1 (enExample)
BR (1) BR112022023897A2 (enExample)
CA (1) CA3184167A1 (enExample)
DK (1) DK3934653T3 (enExample)
ES (1) ES2937145T3 (enExample)
FI (1) FI3934653T3 (enExample)
HU (1) HUE060929T2 (enExample)
IL (1) IL298543A (enExample)
JO (1) JOP20220319B1 (enExample)
LT (1) LT3934653T (enExample)
MX (1) MX2022015074A (enExample)
PL (1) PL3934653T3 (enExample)
RS (1) RS63940B1 (enExample)
SI (1) SI3934653T1 (enExample)
SM (1) SMT202300036T1 (enExample)
WO (1) WO2021239943A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
ES2937145T3 (es) * 2020-05-29 2023-03-24 CEBINA GmbH Azelastina como tratamiento antiviral

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01153639A (ja) * 1987-11-13 1989-06-15 Asta Pharma Ag 鼻又は目に使用する薬剤及びその製造法
JP2008285474A (ja) * 2007-04-17 2008-11-27 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤を含有する医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836579A1 (de) * 1987-11-13 1989-05-24 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8642069B2 (en) * 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
WO2021207213A2 (en) * 2020-04-07 2021-10-14 University Of Florida Research Foundation, Incorporated Methods to prevent sars-cov-2 infection and treat covid-19
US20230142221A1 (en) * 2020-04-10 2023-05-11 Kamal Khan Mubarak Compositions and methods for modulating ace2 receptor
CN113521289A (zh) * 2020-04-16 2021-10-22 中国科学院上海药物研究所 15种药物有效成分在抗病毒感染中的应用
ES2937145T3 (es) * 2020-05-29 2023-03-24 CEBINA GmbH Azelastina como tratamiento antiviral

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01153639A (ja) * 1987-11-13 1989-06-15 Asta Pharma Ag 鼻又は目に使用する薬剤及びその製造法
JP2008285474A (ja) * 2007-04-17 2008-11-27 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤を含有する医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARXIV, QUANTITATIVE BIOLOGY, MOLECULAR NETWORKS, vol. arXiv:2004.07229, JPN6025028517, April 2020 (2020-04-01), ISSN: 0005639619 *
BIOINFORMATION, vol. 16, no. 3, JPN6025028518, March 2020 (2020-03-01), pages 236 - 244, ISSN: 0005639620 *

Also Published As

Publication number Publication date
AU2021279280A1 (en) 2023-01-05
EP3934653A1 (en) 2022-01-12
SMT202300036T1 (it) 2023-03-17
MX2022015074A (es) 2023-02-16
PL3934653T3 (pl) 2023-03-13
US11273163B2 (en) 2022-03-15
EP4190333A1 (en) 2023-06-07
RS63940B1 (sr) 2023-02-28
HUE060929T2 (hu) 2023-04-28
EP3934653B1 (en) 2022-11-09
FI3934653T3 (fi) 2023-03-01
IL298543A (en) 2023-01-01
BR112022023897A2 (pt) 2023-04-04
KR20230021009A (ko) 2023-02-13
ES2937145T3 (es) 2023-03-24
WO2021239943A1 (en) 2021-12-02
SI3934653T1 (sl) 2023-04-28
CN116406273A (zh) 2023-07-07
CA3184167A1 (en) 2021-12-02
JOP20220319B1 (ar) 2024-12-22
US11433080B2 (en) 2022-09-06
US20230201216A1 (en) 2023-06-29
US20210369730A1 (en) 2021-12-02
LT3934653T (lt) 2023-02-27
DK3934653T3 (da) 2023-02-13
US20220143040A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
CN110325187B (zh) N-氨基甲酰亚胺基-5-(1-甲基-1h-吡唑-4-基)-2-萘甲酰胺在制备治疗流感的药物中的用途
Leneva et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses
AU2017325010A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
US9168236B2 (en) Methods and pharmaceutical compositions for inhibiting influenza viruses replication
WO2013044871A1 (zh) 氯喹或氯丙嗪或其衍生物或它们的混合物在制备用于治疗和/或预防肺感染和损伤的药物中的用途
WO2020241759A1 (ja) インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤
US11433080B2 (en) Antiviral treatment
CN112912074A (zh) Egcg-棕榈酸酯组合物及其使用方法
JP7752675B2 (ja) ウイルスに対するタウロリジンの使用
CN114007598A (zh) 用于治疗病毒和细菌感染的新型mek抑制剂
US20230225988A1 (en) Antiviral use of calixarenes
JP7840570B2 (ja) コロナウイルス感染症の処置のための方法
RU2842052C1 (ru) Азеластин в качестве противовирусного лечения
WO2014146218A1 (zh) 马替麦考酚酯或其盐类用于制备抗流感病毒之药物的用途
EP3936132A1 (en) Azelastine as antiviral treatment
HK40087524A (zh) 氮卓斯汀用作抗病毒治疗
CN114377009A (zh) Sb216763在制备抗流感病毒药物中的应用
CN114377015B (zh) 萘哌地尔在制备抗流感病毒药物中的应用
CN117838689A (zh) 培菲替尼在制备治疗流感病毒感染的药物中的应用
KR20250002212A (ko) 인플루엔자 및 폭스바이러스 바이러스 감염을 치료하는 방법
CN121422222A (zh) Dpp4抑制剂在制备治疗或预防孕期呼吸道病毒感染所致妊娠并发症的药物中的用途
WO2020216349A1 (zh) 一种肠道病毒抑制剂
CN117838698A (zh) 奥拉替尼在制备治疗流感病毒感染的药物中的应用
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви
CN117503777A (zh) 化合物在抗病毒中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260422